tiprankstipranks
Trending News
More News >
Sakar Healthcare Ltd (IN:SAKAR)
:SAKAR
India Market
Advertisement

Sakar Healthcare Ltd (SAKAR) AI Stock Analysis

Compare
0 Followers

Top Page

IN:SAKAR

Sakar Healthcare Ltd

(SAKAR)

Rating:61Neutral
Price Target:
₹353.00
▲(6.21% Upside)
Sakar Healthcare Ltd's overall score is driven by strong financial performance, particularly in revenue growth and operational efficiency. However, technical indicators suggest bearish momentum, and the valuation appears high, which tempers the overall score.

Sakar Healthcare Ltd (SAKAR) vs. iShares MSCI India ETF (INDA)

Sakar Healthcare Ltd Business Overview & Revenue Model

Company DescriptionSakar Healthcare Ltd (SAKAR) is a pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company operates in the healthcare sector, focusing on the production of injectable formulations, oral solids, oral liquids, and other pharmaceutical products. Sakar Healthcare is committed to providing quality healthcare solutions and has a presence in both domestic and international markets.
How the Company Makes MoneySakar Healthcare Ltd makes money through the sale of its pharmaceutical products, which include a variety of formulations such as injectables, tablets, capsules, and liquid orals. The company generates revenue by supplying these products to hospitals, clinics, pharmacies, and other healthcare facilities in domestic and international markets. Additionally, Sakar Healthcare engages in contract manufacturing, producing pharmaceutical products for other companies, which serves as an additional revenue stream. The company may also have strategic partnerships or collaborations with other pharmaceutical companies, which can enhance its market reach and contribute to its overall earnings.

Sakar Healthcare Ltd Financial Statement Overview

Summary
Sakar Healthcare Ltd shows strong revenue growth and improving operational efficiency, with increasing EBIT margins and a stable equity position. However, challenges in maintaining consistent profitability and managing cash flow effectively persist.
Income Statement
72
Positive
Sakar Healthcare Ltd has demonstrated a consistent increase in revenue over the years, with a notable revenue growth rate of 15.2% in 2025 compared to 2024, and 15.6% from 2024 to 2023. The Gross Profit Margin has been fluctuating but remained strong, standing at 24.1% for 2025. However, the Net Profit Margin has been lower at 9.9% for 2025, indicating higher operating costs or expenses. The EBIT margin improved to 16.2% in 2025 from 12.9% in 2024, showing operational efficiency. Nonetheless, the drop in Gross Profit Margin from 45.3% in 2024 to 24.1% in 2025 is a concern.
Balance Sheet
68
Positive
The company's Debt-to-Equity ratio has improved, decreasing from 0.30 in 2024 to 0.26 in 2025, indicating a reduction in leverage. The Return on Equity (ROE) has been stable, with 6.1% in 2025, showcasing moderate profitability relative to equity. The Equity Ratio stood at 68.8% in 2025, reflecting a strong equity position. Despite the positive trends, the ratio of Total Debt to Stockholders' Equity remains notable, requiring careful monitoring.
Cash Flow
60
Neutral
The Free Cash Flow has been negative but shows signs of improvement, with a 61.4% increase in 2025 compared to 2024. The Operating Cash Flow to Net Income ratio was strong at 1.07 in 2025, indicating that the company is efficiently converting its net income into cash. However, the Free Cash Flow to Net Income ratio remains negative, suggesting challenges in covering capital expenditures solely through operational earnings.
BreakdownTTMDec 2025Dec 2024Dec 2022Dec 2021Dec 2021
Income Statement
Total Revenue1.70B1.78B1.54B1.33B947.39M1.28B
Gross Profit468.15M427.91M699.59M598.12M432.46M534.12M
EBITDA463.14M509.44M393.27M341.03M237.73M315.72M
Net Income148.62M175.02M116.71M127.59M106.83M152.43M
Balance Sheet
Total Assets0.004.15B3.95B3.36B1.78B2.68B
Cash, Cash Equivalents and Short-Term Investments5.27M3.09M4.66M35.23M824.65K71.36M
Total Debt0.00749.55M793.52M1.11B425.97M928.62M
Total Liabilities-2.69B1.30B1.33B1.63B793.40M1.40B
Stockholders Equity2.69B2.85B2.62B1.73B984.52M1.27B
Cash Flow
Free Cash Flow0.00-135.52M-350.93M-468.81M-209.69M-618.33M
Operating Cash Flow0.00187.31M244.67M353.14M145.77M356.99M
Investing Cash Flow0.00-307.09M-515.39M-743.77M-468.33M-903.72M
Financing Cash Flow0.00118.22M274.45M410.96M320.33M546.21M

Sakar Healthcare Ltd Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price332.35
Price Trends
50DMA
342.85
Negative
100DMA
326.60
Positive
200DMA
300.78
Positive
Market Momentum
MACD
-1.19
Negative
RSI
47.22
Neutral
STOCH
52.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SAKAR, the sentiment is Neutral. The current price of 332.35 is above the 20-day moving average (MA) of 330.50, below the 50-day MA of 342.85, and above the 200-day MA of 300.78, indicating a neutral trend. The MACD of -1.19 indicates Negative momentum. The RSI at 47.22 is Neutral, neither overbought nor oversold. The STOCH value of 52.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:SAKAR.

Sakar Healthcare Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
₹6.17B11.48
9.15%88.32%
62
Neutral
₹6.18B2.97
-68.96%-30.30%
61
Neutral
₹7.30B36.91
21.65%73.16%
57
Neutral
₹6.51B21.85
37.51%122.56%
54
Neutral
₹4.76B47.55
0.29%-9.90%33.18%
51
Neutral
$7.95B-0.40-42.50%2.21%22.29%-1.85%
43
Neutral
₹3.29B30.02
-3.41%-3028.44%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:SAKAR
Sakar Healthcare Ltd
332.35
10.00
3.10%
IN:INDSWFTLAB
Ind-Swift Laboratories Ltd.
102.00
-40.20
-28.27%
IN:KILITCH
Kilitch Drugs (India) Limited
372.35
39.62
11.91%
IN:MEDICAMEQ
Medicamen Biotech Limited
351.15
-77.37
-18.06%
IN:NECLIFE
Nectar Lifesciences Ltd.
14.66
-37.03
-71.64%
IN:VENUSREM
Venus Remedies Limited
461.30
104.45
29.27%

Sakar Healthcare Ltd Corporate Events

Sakar Healthcare Ltd Confirms Compliance with SEBI Regulations for Q2 2025
Jul 10, 2025

Sakar Healthcare Ltd has submitted a confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ending June 30, 2025. This announcement confirms the dematerialization of securities and their listing on stock exchanges, ensuring compliance with regulatory requirements and maintaining transparency for stakeholders.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 22, 2025